KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Free Cash Flow (2020 - 2025)

Aurinia Pharmaceuticals (AUPH) has disclosed Free Cash Flow for 6 consecutive years, with $45.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Free Cash Flow rose 51.69% year-over-year to $45.6 million, compared with a TTM value of $135.4 million through Dec 2025, up 206.99%, and an annual FY2025 reading of $135.4 million, up 206.99% over the prior year.
  • Free Cash Flow was $45.6 million for Q4 2025 at Aurinia Pharmaceuticals, up from $44.4 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at $45.6 million in Q4 2025 and bottomed at -$53.7 million in Q1 2021.
  • Average Free Cash Flow over 5 years is -$4.8 million, with a median of -$8.1 million recorded in 2023.
  • The sharpest move saw Free Cash Flow tumbled 136.6% in 2021, then surged 623.31% in 2024.
  • Year by year, Free Cash Flow stood at -$25.9 million in 2021, then skyrocketed by 139.8% to $10.3 million in 2022, then soared by 35.84% to $14.0 million in 2023, then soared by 114.5% to $30.1 million in 2024, then skyrocketed by 51.69% to $45.6 million in 2025.
  • Business Quant data shows Free Cash Flow for AUPH at $45.6 million in Q4 2025, $44.4 million in Q3 2025, and $44.1 million in Q2 2025.